• Acute Myeloid Leukemia

Dr. Lin has collaborated on translational research projects with Dr. Linheng Li at the Stowers Institute and Dr. John Perry at Children’s Mercy Hospital (A Pilot Study of Low-Dose Daunorubicin in Patients with Relapsed/Refractory Acute Leukemia); with Drs. Joaquina Baranda at KUMC and Tomoo Iwakuma at Children’s Mercy Hospital (Statin use in cancers with mutated TP53); and with Dr. Ramesh Balusu at KUMC (Differentiation therapy with multi-targeted TKI in AML). She is co-author on more than 50 abstracts, 58 publications and 7 book chapters. In 2018 KUMC was selected to join the Beat AML Consortium – a collaboration sponsored by the Leukemia and Lymphoma Society. Beat AML is a highly selective group, with 17 institutions across the country invited to participate. KUMC participated in the translational research collaboration as well as the family of clinical trials under the Beat AML umbrella. Dr. Lin was a co-author on the Beat AML publications "Functional Genomic Landscape in Acute Myeloid Leukemia" published in Nature in 2018 and “Precision Medicine Treatment in Acute Myeloid Leukemia Using Prospective Genomic Profiling” published in Nature Medicine in 2020. KUMC has been involved in clinical trials of 6 drugs recently approved for AML, and Dr. Lin served as the local PI for trials in 5 of those drugs. She was a co-author on the pivotal publications reporting the data which led to FDA approval for CPX-351 (Journal of Clinical Oncology, 2018) and Venetoclax (Journal of Clinical Oncology, 2019). She is an active member of the SWOG Leukemia Committee and serves as Study Chair for the upcoming Myelomatch High Risk AML clinical trial.